Added to YB: 2024-02-02
Pitch date: 2024-02-01
ARGX [bullish]
argenx SE
+112.65%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 354.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
Show full summary:
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
ARGX rebounds on JPM update: Vyvgart hits $1.2B in '23 sales, Hytrulo launch; CIDP results impress (67% response); '24 sales to near $2B; '25 $3B+ possible w/ label expansion. $3.2B cash, B/E '25; 4 new candidates by '25 YE. Aims to solidify spot despite competition.
Read full article (8 min)